Atyr Pharma EBIT

The latest EBIT for LIFE is $-64M as of June 2026. That compares with $-70M in the prior-year period — up 9.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Atyr Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIFE's EBIT moved from $-70M to $-64M — a 9.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Atyr Pharma's operating scale or balance-sheet position.

Against Healthcare companies, LIFE currently prints $-64M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Atyr Pharma's growth, margins, and balance sheet.

A EBIT figure of $-64M for LIFE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting LIFE's EBIT ($-64M), review year-over-year change from $-70M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.